Hormone replacement therapy: the benefits in tailoring the regimen and dose

被引:29
作者
Gambacciani, M [1 ]
Genazzani, AR [1 ]
机构
[1] Univ Pisa, Dept Reprod & Child Dev, Div Obstet & Gynecol Piero Fioretti, I-56100 Pisa, Italy
关键词
HRT; estrogen deprivation; postmenopause;
D O I
10.1016/S0378-5122(01)00281-X
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Despite the clear benefits of long-term hormone replacement therapy (HRT), the majority of patients tend to undergo short-term treatment. The cyclical bleedings induced by the sequential progestogen administration are often unacceptable namely in the elderly postmenopausal women. At the standard doses HRT preparations can also induce annoying hormone-related side effects, both in sequential and continuous combined regimens. Lower HRT schedules are reported to be highly effective in the relief of climacteric symptoms, inducing minimal endometrial stimulation with high rates of amenorrhea. Continuous administration of low doses of progestins is safe for endometrium protection and minimizes progestin-related side effects. Indeed, it has been demonstrated that low dose HRT can prevent the increase in bone turnover and the consequent bone loss in postmenopausal women. The choice of lower HRT dosages can also be useful for the number of potential disadvantages of standard HRT doses, mainly for long-term treatments. Low dose regimens should be considered as a starting dose to minimize the occurrence of side effects, improving compliance and, therefore, HRT effects on the prevention of long-term consequences of estrogen deprivation. (C) 2001 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 53 条
  • [1] ARCHER DF, 1994, OBSTET GYNECOL, V83, P686
  • [2] Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
    Archer, DF
    Dorin, M
    Lewis, V
    Schneider, DL
    Pickar, JH
    [J]. FERTILITY AND STERILITY, 2001, 75 (06) : 1080 - 1087
  • [3] Endometrial safety of continuous combined hormone replacement therapy with 17β-oestradiol (1 or 2 mg) dydrogesterone
    Bergeron, C
    Ferenczy, A
    [J]. MATURITAS, 2001, 37 (03) : 191 - 199
  • [4] Adverse endometrial effects during long cycle hormone replacement therapy
    Bjarnason, K
    Cerin, Å
    Lindgren, R
    Weber, T
    [J]. MATURITAS, 1999, 32 (03) : 161 - 170
  • [5] BUSH T, 1998, 9 N AM MEN SOC M
  • [6] BUSH T, 1999, 10 N AM MEN SOC M
  • [7] NONCONTRACEPTIVE ESTROGEN USE AND CARDIOVASCULAR-DISEASE
    BUSH, TL
    BARRETTCONNOR, E
    [J]. EPIDEMIOLOGIC REVIEWS, 1985, 7 : 80 - 104
  • [8] CAMPBELL S, 1978, POSTGRAD MED J, V54, P59
  • [9] ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN
    CAULEY, JA
    SEELEY, DG
    ENSRUD, K
    ETTINGER, B
    BLACK, D
    CUMMINGS, SR
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) : 9 - 16
  • [10] Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy
    Cerin, A
    Heldaas, K
    Moeller, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (10) : 668 - 669